Market research
KZR Kezar Life Sciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 0.41
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US49372L2097
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 0.41
About
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KZR discussion.
5 years, 4 months ago
Kezar Life Sciences, Inc is currently in a long term downtrend where the price is trading 0.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kezar Life Sciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 14.2% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 29.9% to $-9M since the same quarter in the previous year.
Based on the above factors, Kezar Life Sciences, Inc gets an overall score of 1/5.